Gemtuzumab ozogamicin (GO) with or without interleukin 11 (IL-11) compared with idarubicin plus cytosine arabinoside (IA)
| Variable . | GO without IL-11 (n = 26) . | GO with IL-11 (n = 25) . | IA4-150 (n = 31) . |
|---|---|---|---|
| Median age, y (range) | 72 (65-89) | 71 (65-78) | 72 (65-84) |
| Performance status 3-4 | 6 (23) | 1 (4) | 4 (13) |
| AML (versus MDS) | 20 (77) | 17 (68) | 24 (77) |
| AHD | 18 (69) | 17 (68) | 15 (48) |
| Normal cytogenetic findings | 9 (35) | 11 (44) | 12 (39) |
| Cytogenetic finding of −5/−7 | 7 (27) | 8 (32) | 8 (26) |
| Other cytogenetic abnormalities | 10 (38) | 6 (24) | 11 (35) |
| Treated in laminar-airflow room | 17 (65) | 21 (84) | 14 (45) |
| Complete remission | 2 (8) | 9 (36) | 15 (48) |
| Median survival time, wk (95% CI) | 8 (4-NA) | 15 (5-NA) | 47 (23-116) |
| Variable . | GO without IL-11 (n = 26) . | GO with IL-11 (n = 25) . | IA4-150 (n = 31) . |
|---|---|---|---|
| Median age, y (range) | 72 (65-89) | 71 (65-78) | 72 (65-84) |
| Performance status 3-4 | 6 (23) | 1 (4) | 4 (13) |
| AML (versus MDS) | 20 (77) | 17 (68) | 24 (77) |
| AHD | 18 (69) | 17 (68) | 15 (48) |
| Normal cytogenetic findings | 9 (35) | 11 (44) | 12 (39) |
| Cytogenetic finding of −5/−7 | 7 (27) | 8 (32) | 8 (26) |
| Other cytogenetic abnormalities | 10 (38) | 6 (24) | 11 (35) |
| Treated in laminar-airflow room | 17 (65) | 21 (84) | 14 (45) |
| Complete remission | 2 (8) | 9 (36) | 15 (48) |
| Median survival time, wk (95% CI) | 8 (4-NA) | 15 (5-NA) | 47 (23-116) |
Values are numbers (%) of patients unless otherwise specified.
AML indicates acute myeloid leukemia; MDS, myelodysplastic syndrome; AHD, antecedent hematologic disorder; CI, confidence interval; and NA, not applicable.
CD33 was positive in all 24 of the 31 patients treated with IA in whom it was assessed (median, 96%; range, 36%-100%).